J&J Challenged Over Schizophrenia Drug Patent
J&J filed the suit in early October after Barr informed the company of its Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration. The application included a Paragraph IV certification challenging the validity of J&J’s patent, compelling Barr to inform J&J of its intentions.
The suit was filed against the New Jersey-based generic drug maker by J&J’s...
To view the full article, register now.